U.S. Ascites Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Ascites Market
- ✓Market Size 2024: USD 1.42 billion
- ✓Market Size 2032: USD 2.31 billion
- ✓CAGR: 6.2%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Albumin Supply Contracts: Hospital procurement leaders and albumin distributors should lock multi-year supply agreements with at least two plasma fractionators before the fourth quarter of 2026. Dual-sourcing protects paracentesis service lines against donor-center disruptions and stabilizes outpatient infusion revenue.
Ascites Care in the U.S.: Market Overview
The U.S. ascites market is distinctive because treatment runs as a layered care pathway rather than a single product category. Sodium restriction, spironolactone and furosemide, large-volume paracentesis, and intravenous albumin form the standard sequence set by AASLD guidance. Cirrhosis accounts for roughly 80 percent of U.S. ascites cases, which anchors demand in hospitals and hepatology clinics. The market was valued at USD 1.42 billion in 2024.
Compared with the global norm, the U.S. market concentrates spending in hospitals because most refractory cases require inpatient paracentesis and albumin dosing. Diagnostic and treatment cycles are shorter here than in European single-payer systems, and tunneled peritoneal catheters for malignant ascites achieve strong uptake through comprehensive cancer centers. Medicaid coverage across most states and Medicare hospital reimbursement together determine which care episodes generate revenue.
Growth Drivers in U.S. Ascites Care
Three country-specific drivers sustain demand. First, CDC mortality data show alcohol-associated liver disease deaths rising sharply during the pandemic, with alcohol-related cirrhosis admissions expanding across Appalachian and Southern states. Second, NHANES-based estimates place MASLD prevalence among American adults above 30 percent, feeding a growing pipeline of decompensated cirrhosis patients. Hospitals managing these admissions receive Medicare payments that reward timely paracentesis and albumin administration.
Third, the baby-boomer cohort carries the highest incidence of hepatitis C-related cirrhosis, and direct-acting antiviral programmes reached many of these patients only in the late 2010s. Those patients now present with decompensation at ages where diuretic-refractory ascites is routine. The Inflation Reduction Act's USD 2,000 annual Part D out-of-pocket cap in 2025 improves adherence to long-term oral diuretic regimens, as patients who previously rationed prescriptions now sustain sodium-restricted protocols.
Market Restraints and Entry Barriers
Entry is constrained first by plasma-derived product dependence. Albumin is regulated as a biologic by CBER under 21 CFR Part 640, requiring Biologics License Application approval and facility inspections, so new entrants cannot simply import competing material. Pricing pressure compounds this barrier: generic spironolactone and furosemide sell at pennies per dose, leaving little margin for branded diuretic challengers.
Reimbursement and incumbent advantages add further friction. Albumin purchasing runs through group purchasing organizations such as Vizient and Premier, which reward established plasma suppliers with multi-year contracts. Device entrants face FDA premarket approval for implantable systems, and Sequana Medical's alfapump system has not received U.S. marketing authorization, illustrating how long the clearance path runs.
Market Opportunities in U.S. Ascites Care
Near-term opportunity sits in outpatient and home-based paracentesis, where tunneled catheter placement and drainage kits reduce emergency readmissions. Analyst estimates place the addressable outpatient paracentesis segment near USD 310 million in 2025, growing at roughly 7 percent annually. BD's PleurX-family catheters and Cook Medical drainage systems hold the most established positions in this channel.
Second, the MASH pipeline creates earlier-stage demand for noninvasive fibrosis testing, with FibroScan elastography from Echosens expanding into primary care referral networks. Third, Terlivaz for hepatorenal syndrome, FDA-approved in September 2022 and marketed by Mallinckrodt, opens a hospital-based adjacency for specialists managing ascites complications, estimated at USD 180 million in 2025.
Market at a Glance
| Parameter | Detail |
|---|---|
| Market Size 2024 | USD 1.42 billion |
| Market Size 2032 | USD 2.31 billion |
| Growth Rate (CAGR) | 6.2% |
| Most Critical Decision Factor | Plasma-derived albumin supply security and reimbursement alignment |
| Largest Region | South Census Region |
| Competitive Structure | Concentrated plasma supply; fragmented generic diuretics and device channel |
Leading Market Participants
- Grifols
- CSL Behring
- Octapharma
- Kedrion Biopharma
- Mallinckrodt
- Madrigal Pharmaceuticals
- Sequana Medical
- Becton Dickinson
- Pfizer
- Teva Pharmaceuticals
Regulatory and Policy Environment
FDA oversight splits between CDER for drugs such as spironolactone and resmetirom, CBER for plasma-derived albumin, and CDRH for devices including tunneled catheters and implantable pumps. Standard Biologics License Application review runs 10 months after a 60-day filing period, while a premarket approval review targets 180 FDA days. Albumin manufacturers must also meet CBER lot-release testing and Good Manufacturing Practice requirements before commercial shipment.
Reimbursement is governed by CMS. Paracentesis is billed under CPT 49083 and related codes, while Medicare Part B covers albumin under hospital and outpatient fee schedules. Hospitals must meet Joint Commission standards for infusion services, and state Certificate of Need rules govern new ambulatory procedure capacity in several states, adding a 6 to 12 month approval timeline for new outpatient drainage centers.
Long-Term Outlook for U.S. Ascites Care
By 2032 the U.S. ascites market is projected to reach USD 2.31 billion, with outpatient and home-based paracentesis growing fastest. MASH-driven patients will shift demand toward earlier diagnosis and diuretic-first regimens, while albumin spending plateaus as sodium-restricted protocols reduce volume per episode.
Competitive dynamics will tighten around plasma supply security and device reimbursement. Sequana Medical's alfapump pathway and BD's catheter franchise will determine whether implantable systems become a standard-of-care option. Entrants that secure fractionator partnerships and CPT coding alignment early will hold the strongest positions by 2032.
Frequently Asked Questions
Market Segmentation
- Diuretic Therapy
- Albumin Infusion
- Large-Volume Paracentesis
- Terlipressin Therapy
- Implantable Drainage Systems
- Alcohol-Related Cirrhosis
- MASH-Related Cirrhosis
- Malignant Ascites
- Heart Failure-Associated Ascites
- Nephrotic Syndrome-Related Ascites
- Hospitals
- Ambulatory Surgical Centers
- Hepatology Clinics
- Home Care Settings
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.